Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03832361 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
A Phase 2 study of Endometrial Cancer, sponsored by Alessandro Santin.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT03832361: Recruiting Phase 2 study of Endometrial Cancer, sponsored by Alessandro Santin.
NCT03832361 is a Phase 2 study of Endometrial Cancer that is actively recruiting participants, run by Alessandro Santin. The registered enrollment target is 50 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03832361, a Phase 2 study of Endometrial Cancer, is actively recruiting participants, sponsored by Alessandro Santin.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRα).
Primary Outcome
Objective response rate (complete response and partial response rates) by RECIST 1.1 criteria of mirvetuximab soravtansine in patients with folate receptor α-positive persistent or recurrent endometrial cancer
Conditions Studied
Interventions
- DRUG IMGN853
Study Locations (1)
Connecticut
- Smilow Cancer Hospital at Yale New Haven - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2020-07-15 |
| Est. Completion | 2028-10 |
| Phase | Phase 2 |
What NCT03832361 shows while recruiting
NCT03832361 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which IMGN853 is the first listed.
NCT03832361 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT03832361 about?
NCT03832361 is a clinical study titled "Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer". The purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRα).
What is the current status of trial NCT03832361?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2020-07-15. Estimated completion is 2028-10.
What conditions does trial NCT03832361 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT03832361?
The interventions under investigation include: IMGN853 (DRUG).
Who is sponsoring clinical trial NCT03832361?
This trial is sponsored by Alessandro Santin, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03832361 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03832361's enrollment target sits among peer trials
50 125th of 181 higher than 54 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
RECRUITING · Phase 2
-
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
RECRUITING · Phase 2
-
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI